Agnosia Treatment Market Research, Overview by Recent Opportunities, Growth Size, Regional Analysis and Forecasts to 2030
Market Highlights
The global Agnosia
Treatment Market Research is expected to reach USD 34,976 Million by 2030
at 3.2% CAGR during the forecast period 2022-2030.
Agnosia is a rare neurological disorder; amongst those, the
prevalence rate of visual or auditory agnosia is much higher than the tactile
agnosia. It affects a large number of people all over the world in a year.
Agnosia occurs when the brain suffers damage along certain pathways. The brains
primary sensory processing areas are connects these pathways. These parts are
known to store knowledge and information.
Agnosia is the loss of the ability to recognize objects,
faces, voices, or places. It is a rare disorder which only affect a single
pathway of the brain. The agnosia can be classified into three major types:
visual, auditory, and tactile. Visual agnosia occurs when there is brain damage
to the occipital lobe of the brain. The occipital lobe is responsible for the
incoming visual information. Auditory agnosia is also known as pure word
deafness. It’s the inability to recognize or process sounds despite intact
hearing. Tactile agnosia is the inability to recognize objects by touch.
Lesions in the parietal lobe of the brain are the cause of tactile agnosia.
If the cause of agnosia is properly treated, the recovery
should occur within the first three months, although it may take up to a year.
The success of recovery depends on the type, size, and location of the damage,
the severity of the impairment, the age of the affected person, as well as the
effectiveness of treatment. According to the WHO, treating and caring for
people with dementia currently costs the world more than USD 604 billion per
year.
Regional Analysis
Global agnosia treatment consists of regions namely Americas,
Europe, Asia Pacific, and the Middle East & Africa.
Alzheimer disease has become a major health concern as the
world’s population ages. It is projected that by 2050, the world’s population
people aged above 60 will account for approximately 22% cases of alzheimers and
moreover four-fifths belonging to the developing regions such as Asia, Latin
America or Africa.
North America dominated the global agnosia treatment market.
Brain injury is considered as a major cause for the development of agnosia leading
to the substantial share for the U.S. market. Europe holds the second largest
share of the global agnosia diagnosis & treatment market. According to the
WHO, Europe had an estimated 10 million disease cases in 2010 and based on
United Nation’s demographic forecast this figure will rise to 14 million by
2030.
Asia Pacific is the fastest growing agnosia diagnosis &
treatment market across the globe. The increasing healthcare expenditure, and
government initiatives for research & development will drive the market in
China and India over the period. The Middle East and Africa hold the least
share of the global agnosia treatment market due to limited availability of
medical facilities.
Segmentation
The agnosia treatment market is segmented on the basis of is
segmented on the basis of diagnosis, causes, type, and treatment.
On the basis of diagnosis it is segmented into Computed
Tomography (CT), Magnetic Resonance Imaging (MRI), and others.
On the basis of causes it is segmented into Alzheimer's
disease, Pick's disease, MELAS, Balint's syndrome.
On the basis of the type, it is segmented into auditory
agnosia, gustatory agnosia, olfactory agnosia, tactile agnosia, visual agnosia,
and others. Others is further segmented into prosopagnosia and anosognosia.
On the basis of treatment, it is segmented into surgery,
antibiotics for cerebral absess and radiation of brain tumor. Antibiotics for
cerebral absess is further segmented into Ceftriaxone and
Cefotaxime+metronidazole.
Key Players
Some of key the players in the global agnosia treatment
market are B. Braun Melsungen (Germany), Pfizer Inc. (U.S.), Lupin ltd.
(India), Fujifilm Holdings (Japan), GE Healthcare (U.S.), Siemens
Healthcare(U.S.), Philips Healthcare (U.S.), F. Hoffmann-La Roche AG
(Switzerland) , Aurobindo Pharma Ltd (India), Sandoz GmBH (Austria), Stellar-
Bio Labs (India), Fresenius Kabi Ipsum SRL (Italy), Zhuhai United Laboratories
Co Ltd (China), Cspc Zhongnuo Pharmaceutical Shijiazhuang Co Ltd (China), IPCA
Labs ltd. (India) and others.
About US:
Market Research Future (MRFR) enable customers to unravel
the complexity of various industries through Cooked Research Report (CRR),
Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed
Research (CFR), and Market Research & Consulting Services.
Contact us:
Market Research Future (part of Wantstats Research and Media
Private Limited),
99 Hudson Street,5Th Floor, New York,
New York 10013
Comments
Post a Comment